Rigaku Collaborates on X-ray Analysis of Fusuma-e by Maruyama Okyo
TOKYO — Rigaku Corporation, a global solution partner in X-ray analytical devices and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter 'Rigaku') has conducted measurements of fusuma-e in Daijoji, a temple in Mikata-gun, Hyogo Prefecture. Fusuma-e, also called shohekiga, are images drawn on fusuma, traditional sliding partitions.
Article content
Article content
The measurements were conducted as part of a research project to 'restore the original colors of the gold-leaf backing of fusuma-e drawn by Maruyama Okyo (1733–1795), a painter of the mid to late Edo period. The project is being conducted through the collaboration of three researchers: Shinno Yamasoba, assistant chief priest of Daijoji Temple and project leader; Tetsuya Senda, formerly of the National Maritime Research Institute; and Takeshi Tanaka, artist and professor at Tohoku University of Art & Design.
Article content
The purpose of the measurements was to investigate scientifically the artistic intention of Maruyama Okyo, the historical context in which he painted, and the impact that restoration would have. The team used the Thermo Scientific™ Niton™ XL5 Plus, a handheld X-ray fluorescence (XRF) analyzer, for its ability to analyze material composition non-destructively. Detailed data were acquired, focusing on the following three areas of interest.
Article content
The team measured to determine whether the gold foil used in the two center panels and the two end panels were of the same or different composition. Confirmation that the compositions are different would provide scientific evidence that the fusuma-e were produced at different times.
Article content
Preliminary measurements suggest that gold foil was used on panels with colored drawings of basho (Japanese fiber banana) to produce a bright, reddish tinge, and on panels with ink drawings of peacocks to create a dark, bluish aspect. In this measurement, the compositions of all fusuma were analyzed to examine further whether different color gradations of gold foil were used in two-panel spaces to create perspective (sense of depth). The results are expected to lead to fresh understanding of the expressive techniques of Okyo.
Article content
The team compared the gold foil Okyo used in the original paintings in the Edo era with the gold foil used in repairs in the early Meiji era (mid-to-late 19 th century). This measurement was a precious opportunity to obtain quantitative data on the gold foil used in the Edo era.
Article content
These analytical results are expected to be used as a scientific resource to deepen understanding of the painting aches and techniques of Maruyama Okyo.
Article content
Rigaku will continue to contribute to the preservation of cultural treasures and transmission of them to future generations through science and technology.
Article content
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations 'To Improve Our World by Powering New Perspectives.'
For details, please visit rigaku-holdings.com/english
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
6 days ago
- Globe and Mail
Rocket Lab's Electron Strengthens Grip on Small Launch Market
Rocket Lab USA, Inc. ( RKLB ) has emerged as an industry forerunner in the launch and space systems market. In the launch segment, Rocket Lab has built a strong position through its small satellite launch services offered by the Electron rocket, which is currently the second most frequently launched U.S. rocket. The growing demand for Rocket Lab's services involving its Electron rocket is evident from several recent developments. In February 2025, the company secured a major contract from a Japan-based Earth imaging company, iQPS. This agreement covers eight dedicated Electron launches, with six missions scheduled for 2025 and two in 2026, making it one of the largest Electron launch deals to date. In June, RKLB successfully launched its 68th Electron rocket to deploy a single satellite to space for a confidential commercial customer. In the same month, Rocket Lab got selected to launch a dedicated Electron mission for the European Space Agency (ESA) for the first time, to deploy the first pair of satellites for a future navigation constellation for Europe. Rocket Lab will conduct these launches, no earlier than December 2025. With such high-profile contracts in its order book, Rocket Lab's Electron rocket cements its dominance in the small launch market, proving its reliability and scalability as the demand for dedicated, agile satellite deployment grows. Other Stocks to Keep on the Watchlist In the modern era of space exploration, factors such as rapid technological advancements, rising demand for satellite deployment, increasing commercial space activities and growing investment in space infrastructure are driving the expansion of the space launch services market. Apart from RKLB, other industry players like Boeing ( BA ) and Lockheed Martin ( LMT ), which already have a well-established presence in the launch services sector, are also positioned to benefit from these growth trends. Their joint venture, the United Launch Alliance (ULA), has been a key U.S. launch provider, successfully delivering more than 150 Atlas and Delta rockets since its formation in 2006. ULA's latest offering, the Vulcan rocket, is an evolution of the Atlas V and Delta IV vehicles. It is designed to provide more affordable and accessible launch options for a variety of missions, further strengthening ULA's competitive standing in the market. RKLB's Price Performance, Valuation and Estimates Shares of RKLB have gained 637.6% in the past year compared with the industry 's 43.3% growth. The company shares are expensive on a relative basis, with its forward 12-month Price/Sales being 26.45X compared with its industry's average of 10.16X. The Zacks Consensus Estimate for RKLB's 2025 loss has improved over the past 60 days. RKLB stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report Rocket Lab Corporation (RKLB): Free Stock Analysis Report
CTV News
30-07-2025
- CTV News
McGill University team develops AI that can detect infection before symptoms appear
Participants wore a smart ring, a smart watch, and a smart T-shirt that monitored multiple physiological parameters and activities. In the photo, an Apple Watch in 2015 in Tokyo. (Koji Sasahara, File/AP Photo) MONTRÉAL — Researchers at McGill University say they developed an artificial intelligence platform that can predict when someone is about to come down with a respiratory tract infection before they start to feel sick. In what researchers are calling a 'world first,' the study involved participants who wore a ring, a watch and a T-shirt, all of which were equipped with censors that recorded their biometric data. By analyzing the data, researchers were able to accurately predict acute systemic inflammation — an early sign of a respiratory infection such as COVID-19. Published in The Lancet Digital Health, the study says the AI platform can one day help doctors address health problems much earlier than they normally would, particularly in patients who are fragile and for whom a new infection could have serious consequences. It could also potentially reduce costs for the health-care system by preventing complications and hospitalizations. 'We were very interested to see if physiological data measured using wearable sensors … could be used to train an artificial intelligence system capable of detecting an infection or disease resulting from inflammation,' explained the study's lead author, Prof. Dennis Jensen of McGill University's department of kinesiology and physical education. 'We wondered if we could detect early changes in physiology and, from there, predict that someone is about to get sick.' Jense says the AI model his team created is the first in the world to use physiological measures — including heart rate, heart rate variability, body temperature, respiratory rate, blood pressure — rather than symptoms, to detect a problem. Acute systemic inflammation is a natural defence mechanism of the body that usually resolves on its own, but it can cause serious health problems, especially in populations with pre-existing conditions. 'The whole idea is kind of like an iceberg,' Jensen said. 'Kind of when the ice cracks the surface, that's like when you're symptomatic, and then it's too late to really do much to treat it.' During the study, McGill researchers administered a weakened flu vaccine to 55 healthy adults to simulate infection in their bodies. The subjects were monitored seven days before inoculation and five days after. Participants wore a smart ring, smart watch, and a smart T-shirt simultaneously throughout the study. As well, researchers collected biomarkers of systemic inflammation using blood samples, PCR tests to detect the presence of respiratory pathogens, and a mobile app to collect symptoms reported by participants. In total, more than two billion data points were collected to train machine learning algorithms. Ten different AI models were developed, but the researchers chose the model that used the least amount of data for the remainder of the project. The chosen model correctly detected nearly 90 per cent of actual positive cases and was deemed more practical for daily monitoring. On their own, Jensen said, none of the data collected from the ring, watch, or T-shirt alone is sensitive enough to detect how the body is responding. 'An increase in heart rate alone may only correspond to two beats per minute, which is not really clinically relevant,' he explained. 'The decrease in heart rate variability can be very modest. The increase in temperature can be very modest. So the idea was that by looking at … several different measurements, we would be able to identify subtle changes in physiology.' The algorithms also successfully detected systemic inflammation in four participants infected with COVID-19 during the study. In each case, the algorithms flagged the immune response up to 72 hours before symptoms appeared or infection was confirmed by PCR testing. Ultimately, the researchers hope to develop a system that will inform patients of possible inflammation so they can contact their health-care provider. 'In medicine, we say that you have to give the right treatment to the right person at the right time,' Jensen said. By expanding the therapeutic window in which doctors can intervene, he added, they could save lives and achieve significant savings by avoiding hospitalizations and enabling home management of chronic conditions or even aging. 'In a way, we hope to revolutionize personalized medicine.' This report by The Canadian Press was first published July 30, 2025. By Jean-Benoit Legault, The Canadian Press
Globe and Mail
23-07-2025
- Globe and Mail
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern's RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern's strategic partnership potential. To view the full press release, visit About Lantern Pharma Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company's proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern's newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program. NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company's newsroom at About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
